打开APP

Virobay第二轮融资加速开发自身免疫病疗法

  1. Virobay
  2. 药物研发
  3. 融资

来源:生物谷 2014-07-20 12:11

Virobay第二轮融资加速开发自身免疫病疗法

2014年7月20日讯 /生物谷BIOON/ --总部设在美国加州门罗帕克的生物技术公司Virobay公司最近第二轮融资又有新进展,著名风投公司Perceptive Advisors牵头TPG Biotech与艾伯维等公司再向Virobay公司投入800万美元,使其第二轮融资总额达到1800万美元左右。

利用这笔资金,Virobay公司将开发期正处于临床一期研究的用于治疗自身免疫药物VBY-036和治疗纤维化和非酒精性脂肪肝疾病的VBY-376。同时Virobay公司目前还正在研究治疗胆汁性肝硬化的药物等。这些处于研发阶段的药物都是基于Virobay公司的蛋白酶小分子抑制物开发技术获得的。

Virobay公司成立于2006年,是Celera Genomics公司业务剥离后的产物。(生物谷Bioon.com)

详细英文报道:

Menlo Park, CA, biotech Virobay tacked another $8 million onto its Series B financing, collecting cash to advance its treatments for neuropathic pain, autoimmune disease and fibrosis.

The latest tranche brings Virobay's B round to $18 million in total, adding new investor Perceptive Advisors to a syndicate that includes TPG Biotech, Alta Partners and AbbVie ($ABBV).

With the new money, Virobay plans to hit the gas on its pipeline of Phase I protease inhibitors, including VBY-036, a treatment for pain and autoimmunity, and VBY-376, which has applications in fibrosis and nonalcoholic steatohepatitis (NASH).

The biotech also has a preclinical candidate for primary biliary cirrhosis and discovery-stage assets for autoimmune disease, cancer and Alzheimer's disease. Virobay's most advanced treatment is the Phase I psoriasis treatment VBY-091, licensed to Denmark's Leo Pharma in a deal worth up to $307 million.

Each candidate is based on Virobay's platform for developing small-molecule inhibitors of cathepsins, a subclass of proteases that play a role in cellular function and are implicated in a variety of diseases.

The company, founded in 2006 as a spinout of Celera Genomics, operates under the virtual model, maintaining a small in-house staff and tapping external contractors to do the heavy lifting.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->